Skip to main content
. 2018 Dec 24;116(2):619–624. doi: 10.1073/pnas.1814027116

Fig. 4.

Fig. 4.

GS-626510 and JQ1 inhibited cell proliferation in primary ovarian carcinoma cell lines in vitro and in ovarian cancer xenografts and PDXs in vivo. (A and B) IC50 for GS-626510 and JQ1 of primary carcinoma cell lines incubated for 72 h with varying concentrations of GS-626510 and JQ1. (C and D) Tumor growth inhibition of OSC-KRCH31, a chemotherapy-resistant tumor cell line established from a patient experiencing progressive disease in vivo. (E) Tumor growth inhibition of OSC-OMM78, a chemotherapy-resistant PDX established from a patient experiencing progressive disease in vivo. (F) Overall survival of animals harboring OSC-OMM78 PDX and treated with GS-626510 vs. placebo control. *P < 0.05.